Burosumab, a fully humanized immunoglobin G1 monoclonal antibody to FGF23, is predominantly used in the management of paediatric and adult patients with XLH and ameliorates many of the clinical features, including hypophosphataemia and rickets.15 This evidence concerns the gene FGF23 and rickets.